LENZ Therapeutics Shares Third Quarter Financial Results, Highlights VIZZ Approval and Launch

SAN DIEGO—LENZ Therapeutics, Inc. (Nasdaq: LENZ), the pharmaceutical company focused on the commercialization of recently FDA-approved VIZZ (aceclidine ophthalmic solution) 1.44%, has announced financial results for the third quarter ending September 30, 2025, as well as recent corporate highlights. Highlighted among those was the FDA approval in late July of VIZZ, an aceclidine-based eye drop for the treatment of presbyopia in adults, as well as its commercial product launch initiated in October. In sharing yesterday’s financial and corporate updates, the company reported pro forma cash, cash equivalents and marketable securities of approximately $324.0 million as of September 30, 2025, which the company said is anticipated to fund operations to post-launch positive cash flow.